Post-earnings recap
Reported
Fri, May 11, 2018
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
75%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Denali Therapeutics reported a loss of $0.26 per share, which was in line with expectations, but the lack of revenue figures and guidance contributed to a negative stock reaction. The stock fell by 5.17% as investors may be concerned about the company's future performance and pipeline advancements without clear financial direction. Overall, the cautious tone from management suggests that investors should be prepared for continued volatility in the near term.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.26 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Management expressed a cautious outlook, emphasizing the importance of their ongoing projects. They did not provide any updates on future guidance.
Management did not provide specific revenue guidance for the upcoming quarters.
The company remains focused on advancing its pipeline despite the current financial performance.